This post was just published on ZYX Buy Change Alert. There was no fill on JUNO IPO as the IPO was priced above the maximum we were willing to pay. Therefore this call is now cancelled. You are receiving less than 2% of the content from our paid services …TO RECEIVE
This post was just published on ZYX Short Change Alert. VA is an airline and benefiting from lower oil prices. However this is the best short idea if oil spikes higher in the short-term. Please note that the float is small and therefore potential of short squeeze is high. Only
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers. ) SANTA CLAUS RALLY CONTINUES December 26, 2014 Santa Claus rally continues in stock markets across the world. Our volume based indicators are beginning to
Merry Christmas and Happy Holidays from all of us at The Arora Report.
(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers. ) FORTUITOUS TIMING BEFORE THE MONSTER RALLY BUT SHY AWAY FROM EXUBERANCE December 19, 2014 In two days, the stock market rose about 700 DJIA
In two days, the stock market rose about 700 DJIA points from the low. On the day of the low, ZYX Buy Change Alert headline, “NO STOCK MARKET CRASH, ANY FURTHER DIP WILL BE A BUYING OPPORTUNITY, AND REDUCING THE HEDGE.” The above chart tells the story. You are receiving
This post was just published on ZYX Buy Change Alert. BLCM is long with an average price of $19. As of this writing it is trading at $25.84. Consider taking profits on a 20% tranche in the zone of $25 to $26.73. Also consider stops on a 20% tranche in the
This post was published on ZYX Buy Change Alert. JUNO is developing immunotherapies for lymphomas, leukemias and other cancers. It is an upcoming IPO This is a call to buy in the IPO at the IPO price. To be clear, this is not a call to buy the stock post IPO
This post was published on ZYX Buy Change Alert. BLCM is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. It is an upcoming IPO This is a
This post was just published on ZYX Buy Change Alert. RAD is long from an average of $4.96 and 70% of the full core position size is being held. In the premarket as of this writing RAD is trading at $6.72. Consider taking profits on a 10% tranche in the zone